FrancophonIA/ELRC3.0 huggingface dataset:
English: Serious infections have been observed in patients receiving secukinumab in the post-marketing setting.
Croatian: U bolesnika koji su primali sekukinumab u periodu nakon stavljanja lijeka u promet bile su uočene ozbiljne infekcije.
English: In both study 3 and study 4, patients randomised to secukinumab received 150 mg or 300 mg doses at weeks 0, 1, 2, 3 and 4, followed by the same dose every month.
Croatian: I u 3. i 4. ispitivanju bolesnici randomizirani na sekukinumab primali su doze od 150 mg ili 300 mg u 0., 1., 2., 3. i 4. tjednu, nakon čega je slijedila ista doza svakog mjeseca.
English: Patients randomised to secukinumab received 75 mg, 150 mg or 300 mg subcutaneously at weeks 0, 1, 2, 3 and 4, followed by the same dose every month.
Croatian: Bolesnici randomizirani na sekukinumab primali su 75 mg, 150 mg ili 300 mg supkutano u 0., 1., 2., 3. i 4. tjednu, nakon čega je slijedila ista doza svaki mjesec.
English: Patients randomised to receive placebo who were responders at week 16 were crossed over to receive secukinumab (either 150 mg or 300 mg subcutaneously) at week 24 followed by the same dose every month.
Croatian: Bolesnici randomizirani na primanje placeba koji su imali odgovor u 16. tjednu prešli su na primanje sekukinumaba (150 mg ili 300 mg supkutano) u 24. tjednu, nakon čega je slijedila ista doza svaki mjesec.
English: Multipack: 6 (3 packs of 2) pre-filled syringes
Croatian: Višestruko pakiranje: 6 (3 pakiranja po 2) napunjenih štrcaljki
English: Patients randomised to placebo who were non-responders at week 16 (early rescue) and other placebo patients at week 24 were crossed over to receive secukinumab (either 75 mg or 150 mg subcutaneously) followed by the same dose every month.
Croatian: Bolesnici randomizirani na placebo koji nisu imali odgovor u 16. tjednu (ranija primjena sekukinumaba) i drugi bolesnici na placebu u 24. tjednu su prebačeni na sekukinumab (75 mg ili 150 mg supkutano), nakon čega je slijedila ista doza svaki mjesec.
English: Store the pens in the original package in order to protect from light.
Croatian: Čuvati štrcaljke u originalnom pakiranju radi zaštite od svjetlosti.
English: Store the syringe sealed in its box to protect from light.
Croatian: Napunjenu štrcaljku čuvati u kutiji radi zaštite od svjetlosti.
English: PASI 100 response n(%) 0 (0.0%) 10
Croatian: Odgovor PASI 100 n(%) 0 (0,0%) 10
English: Number of patients randomised
Croatian: Postotak bolesnika s odgovorom
English: Respiratory, thoracic and mediastinal disorders
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja često rinoreja
English: Storage of the Cosentyx pre-filled syringe
Croatian: Čuvanje Cosentyx napunjene štrcaljke
English: Patients randomised to secukinumab received 75 mg or 150 mg subcutaneously at weeks 0, 1, 2, 3 and 4, followed by the same dose every month.
Croatian: Bolesnici randomizirani na sekukinumab primali su 75 mg ili 150 mg supkutano u 0., 1., 2., 3. i 4. tjednu, nakon čega je slijedila ista doza svakoga mjeseca.
English: In AS study 1 and study 2, patients treated with secukinumab 150 mg showed improvements in healthrelated quality of life as measured by AS Quality of Life Questionnaire (ASQoL) (p=0.001) and SF-36 Physical Component Summary (SF-36PCS) (p<0.001).
Croatian: AS Quality of Life Questionnaire, ASQoL) (p=0,001) i SF-36 Upitnika zbirne komponente tjelesnog zdravlja (engl.
English: PsA study 3
Croatian: 3. ispitivanje PsA
English: Store this medicine sealed in its outer box to protect it from light.
Croatian: Čuvajte ovaj lijek u originalno zalijepljenoj kutiji radi zaštite od svjetlosti.
English: Do not use if the liquid contains easily visible particles, is cloudy or is distinctly brown.
Croatian: Ne upotrebljavajte ako tekućina sadrži lako vidljive čestice, ako je zamućena ili izrazito smeđa.
English: Patients randomised to secukinumab received 150 mg or 300 mg doses at weeks 0, 1, 2, 3 and 4, followed by the same dose every month.
Croatian: Bolesnici randomizirani na sekukinumab primali su doze od 150 mg ili 300 mg u 0., 1., 2., 3. i 4. tjednu, nakon čega je slijedila ista doza svakoga mjeseca.
English: Cosentyx 150 mg powder for solution for injection secukinumab
Croatian: Cosentyx 150 mg prašak za otopinu za injekciju sekukinumab
English: ACR20 response n (%)
Croatian: Broj randomiziranih bolesnika Odgovor ACR20 n (%)
English: Instructions for administration of Cosentyx solution Tilt the vial to an angle of approximately 45° and position the needle tip at the very bottom of the solution in the vial when drawing the solution into the syringe.
Croatian: Nagnite bočicu pod kutem od otprilike 45° i postavite vršak igle na dno otopine u bočici kada izvlačite otopinu u štrcaljku.
English: One vial contains 150 mg secukinumab.
Croatian: Jedna bočica sadrži 150 mg sekukinumaba.
English: Diarrhoea Uncommon Inflammatory bowel disease
Croatian: Poremećaji imunološkog sustava rijetko anafilaktičke reakcije
English: What Cosentyx looks like and contents of the pack Cosentyx solution for injection is a clear liquid.
Croatian: Cosentyx otopina za injekciju je bistra tekućina.
English: Patients randomised to receive placebo who were non-responders at week 16 (early rescue) were crossed over to receive secukinumab (either 150 mg or 300 mg subcutaneously) at week 16 followed by the same dose every month.
Croatian: Bolesnici randomizirani na primanje placeba koji nisu imali odgovor u 16. tjednu (ranija primjena sekukinumaba) prebačeni su na sekukinumab (150 mg ili 300 mg supkutano) u 16. tjednu, nakon čega je slijedila ista doza svaki mjesec.
English: Store the pen sealed in its box to protect from light.
Croatian: Napunjenu brizgalicu čuvati u kutiji radi zaštite od svjetlosti.
English: • oral thrush (oral candidiasis)
Croatian: • infekcija usta gljivicom kandidom (oralna kandidijaza)
English: Each pre-filled syringe contains 150 mg secukinumab.
Croatian: Jedna napunjena brizgalica sadrži 150 mg sekukinumaba.
English: Number of patients PASI 50 response n (%) 22
Croatian: Odgovor PASI 50 n (%) 22
English: Cosentyx 150 mg solution for injection in pre-filled syringe secukinumab
Croatian: Cosentyx 150 mg otopina za injekciju u napunjenoj štrcaljki sekukinumab
English: Instructions for use of Cosentyx pre-filled syringe
Croatian: Upute za primjenu otopine Cosentyx
English: All p-values are adjusted for multiplicity of testing based on pre-defined hierarchy at week 24 for PsA study 2, except for ACR70, Dactylitis and Enthesitis, which were exploratory endpoints and all endpoints at week 16.
Croatian: * p<0,05, ** p<0,01, *** p<0,001; u odnosu na placebo Sve p-vrijednosti prilagođene su za višestrukost testiranja na temelju unaprijed definirane hijerarhije u 24. tjednu za 2. ispitivanje PsA, osim za ACR70, daktilitis i entezitis, koji su bili eksploratorne mjere ishoda te za sve mjere ishoda u 16. tjednu.
English: Syringe guard wings
Croatian: Krilca štitnika štrcaljke
English: Cosentyx 150 mg solution for injection in pre-filled syringe
Croatian: Cosentyx 150 mg otopina za injekciju u napunjenoj štrcaljki
English: - The other ingredients are trehalose dihydrate, histidine, histidine hydrochloride monohydrate,
Croatian: - Drugi sastojci su trehaloza dihidrat, histidin, histidinklorid hidrat, metionin, polisorbat 80 i voda za injekcije.
English: Ustekinumab*
Croatian: Nuspojava
English: Lower respiratory tract infections Not known Mucosal and cutaneous candidiasis (including oesophageal candidiasis)
Croatian: Infekcije i infestacije vrlo često infekcije gornjeg dijela dišnog sustava često oralni herpes manje često oralna kandidijaza tinea pedis upala vanjskog uha infekcije donjih dišnih puteva nepoznato mukokutana kandidijaza (uključujući ezofagealnu kandidijazu)
English: Single use.
Croatian: Za supkutanu primjenu Jednokratna primjena.
English: Each pre-filled syringe contains 150 mg secukinumab in 1 ml.
Croatian: Jedna napunjena brizgalica sadrži 150 mg sekukinumaba u 1 ml.
English: One pre-filled syringe contains 150 mg secukinumab in 1 ml of solution.
Croatian: Jedna napunjena štrcaljka sadrži 150 mg sekukinumaba u 1 ml otopine.
English: Number of patients with ≥3% BSA psoriasis skin involvement at baseline
Croatian: DAS28-CRP 16. tjedan 24. tjedan Broj bolesnika s ≥3% BSA zahvaćenosti kože psorijazom na početku
English: Keep the pre-filled syringe in the outer carton in order to protect from light.
Croatian: Štrcaljku čuvati u originalno zalijepljenoj kutiji radi zaštite od svjetlosti.
English: Cosentyx 150 mg solution for injection in pre-filled pen secukinumab
Croatian: Cosentyx 150 mg otopina za injekciju u napunjenoj brizgalici sekukinumab
English: Each vial of powder contains 150 mg secukinumab.
Croatian: Jedna bočica praška sadrži 150 mg sekukinumaba.
English: Rare
Croatian: Cjepiva
English: Cosentyx 150 mg solution for injection in pre-filled pen
Croatian: Cosentyx 150 mg otopina za injekciju u napunjenoj brizgalici
English: Keep the pre-filled pen in the outer carton in order to protect from light.
Croatian: Brizgalicu čuvati u originalno zalijepljenoj kutiji radi zaštite od svjetlosti.
English: - Headache and muscular pain.
Croatian: - Glavobolja i bol u mišićima.
English: Paresthesia, neuritis
Croatian: Parestezije, neuritis
English: - This vaccine has been prescribed for you only.
Croatian: Ovo je cjepivo propisano samo Vama.
English: Do not place fingers on the windows.
Croatian: Ne stavljajte prste na prozorčiće.
English: Pack size of 1 or 10 or 20.
Croatian: Veličine pakovanja od 1, 10 ili 20.
English: Orient the needle away from you and others.
Croatian: Okrenite iglu od sebe i drugih.
English: Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.
Croatian: Pažljivo pročitajte cijelu uputu prije nego počnete primjenjivati ovo cjepivo jer sadrži Vama važne podatke.
English: * propagated in fertilised hens' eggs from healthy chicken flocks
Croatian: * umnoženi na oplođenim kokošjim jajima od zdravih pilećih jata
English: • Any of the other ingredients of this vaccine (listed in section 6),
Croatian: Bilo koji sastojak ovog cjepiva (naveden u dijelu 6.),
English: Always use this vaccine exactly as your doctor or pharmacist has told you.
Croatian: Uvijek primijenite ovo cjepivo točno onako kako su Vam rekli Vaš liječnik ili ljekarnik.
English: The recommended site of administration is the region of the deltoid.
Croatian: Preporučeno mjesto primjene je područje deltoida.
English: Seroprotection is generally obtained within 2 to 3 weeks.
Croatian: Seroprotekcija se uglavnom postiže unutar 2-3 tjedna.
English: Date of latest renewal: 24 February 2014
Croatian: Datum posljednje obnove odobrenja 24. veljače 2014.
English: Overdose is unlikely to have any untoward effect.
Croatian: Nije vjerojatno da predoziranje ima bilo kakav nepovoljan učinak.
English: Children and adolescents IDflu is not recommended for use in children and adolescents below 18 years.
Croatian: Djeca i adolescenti IDflu se ne preporučuje za primjenu u djece i adolescenata mlađih od 18 godina.
English: * In some cases, local redness lasted up to 7 days.
Croatian: * u nekim je slučajevima lokalno crvenilo bilo prisutno do 7 dana.
English: The use of IDflu should be based on official recommendations.
Croatian: IDflu se mora primjenjivati u skladu sa službenim preporukama.
English: Interference with serological testing: See section 4.5.
Croatian: Za interferenciju sa serološkim testiranjima vidjeti dio 4.5.
English: Like all medicines, this vaccine can cause side effects, although not everybody gets them.
Croatian: Kao i svi lijekovi, ovo cjepivo može izazvati nuspojave, iako se one ne pojavljuju kod svakoga.
English: Micro-Injection System
Croatian: Mikroinjekcijski sustav
English: In the absence of compatibility studies, this medicinal product must not be mixed with other
Croatian: Zbog nedostatka ispitivanja kompatibilnosti, ovaj lijek se ne smije miješati s drugim lijekovima.
English: What IDflu is and what it is used for
Croatian: Što je IDflu i za što se koristi
English: What you need to know before you use IDflu
Croatian: Što morate znati prije nego počnete primjenjivati IDflu
English: What IDflu looks like and contents of the pack
Croatian: Kako IDflu izgleda i sadržaj pakovanja
English: IDflu is not recommended for use in children and adolescents below 18 years due to insufficient data on safety and efficacy.
Croatian: IDflu se ne preporučuje za primjenu u djece i adolescenata mlađih od 18 godina zbog nedostatnih podataka o sigurnosti primjene i djelotvornosti.
English: B A/New Caledonia/ 20/99 A/Wisconsin/ 67/2005 B/Malaysia/ 2506/2004 N = 2,586
Croatian: B A/New Caledonia/20/99 A/Winconsin/67/2005 B/Malaysia/2506/ 2004 N=2586
English: 4/ INJECT USING THE INDEX FINGER
Croatian: 4/ INJICIRAJTE KORISTEĆI KAŽIPRST
English: Keep the syringe in the outer carton in order to protect from light.
Croatian: Štrcaljku čuvati u vanjskom pakovanju radi zaštite od svjetlosti.
English: The vaccine is a colourless and opalescent suspension.
Croatian: Cjepivo je bezbojna i opalescentna suspenzija.
English: Fertility and toxicity studies to reproduction in females have not identified any specific potential hazard for humans.
Croatian: Istraživanja utjecaja na plodnost i toksičnost za reprodukciju u žena nisu utvrdila nikakvu posebnu potencijalnu opasnost za ljude.
English: 4.5 Interaction with other medicinal products and other forms of interaction IDflu may be given at the same time as other vaccines.
Croatian: 4.5. Interakcije s drugim lijekovima i drugi oblici interakcija IDflu se može dati istovremeno s drugim cjepivima.
English: IDflu is administered to you by your doctor or nurse.
Croatian: IDflu će Vam aplicirati liječnik ili medicinska sestra.
English: - If you have an illness with fever or acute infection, the vaccination shall be postponed until
Croatian: - Ako bolujete od bolesti praćene vrućicom ili akutne infekcije, cijepljenje će biti odgođeno dok
English: - Feeling generally unwell, fever (38.0°C or higher) and shivering.
Croatian: - Opće loše osjećanje, povišena temperatura (38,0ºC ili viša) i drhtavica.
English: In repeated-dose toxicity studies in rabbits there was no significant evidence of systemic toxicity.
Croatian: U ispitivanjima toksičnosti ponavljanih doza na kunićima nije zabilježen dokaz značajne sistemske toksičnosti.
English: Genotoxicity and carcinogenic potential were not assessed because these studies are not appropriate for a vaccine.
Croatian: Potencijalna genotoksičnost i kancerogenost nisu utvrđivane jer ta ispitivanja nisu primijenjiva za cjepiva.
English: You should see your doctor immediately if you experience symptoms of angioedema, such as:
Croatian: Odmah se javite svom liječniku ukoliko imate simptome angioedema navedene dolje:
English: What IDflu contains
Croatian: Što IDflu sadrži:
English: When an injection of IDflu is given, the immune system (body's natural defences) will develop
Croatian: Kada osoba primi cjepivo IDflu, imunološki sustav (prirodni tjelesni sustav obrane) stvorit će vlastitu
English: Detailed information on this vaccine is available on the European Medicines Agency web site:
Croatian: Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove
English: Most of side effects listed above disappeared without treatment within 1 to 3 days after onset.
Croatian: Većina gore navedenih nuspojava nestale su bez liječenja unutar 1 do 3 dana nakon pojave.
English: Safety evaluation was performed for all subjects during the first 3 weeks following vaccination and serious adverse reactions were collected during six months of follow-up for 2,974 subjects (population of two out of the three clinical trials).
Croatian: Sigurnosna procjena provedena je u svih ispitanika tijekom prva 3 tjedna nakon cijepljenja, a ozbiljne nuspojave su prikupljane tijekom 6 mjeseci praćenja 2 974 ispitanika koji su cijepljeni (populacija dvije od tri kliničke studije).
English: Precautions to be taken before handling or administering the medicinal product For instructions on preparation of the medicinal product before administration, see section 6.6.
Croatian: Mjere opreza koje treba poduzeti prije rukovanja ili primjene lijeka Za upute o pripremi cjepiva prije primjene, vidjeti dio 6.6.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 24 February 2009
Croatian: Datum prvog odobrenja 24. veljače 2009.
English: Immunisation shall be postponed in subjects with febrile illness or acute infection.
Croatian: Cijepljenje treba odgoditi u osoba s febrilnom bolesti ili akutnom infekcijom.
English: SPECIAL STORAGE CONDITIONS Store in refrigerator.
Croatian: Čuvati u hladnjaku.
English: Based on the experience with trivalent inactivated influenza vaccines administered by intramuscular or deep subcutaneous injection, the following events may be reported:
Croatian: Temeljem iskustva s trovalentnim inaktiviranim cjepivom protiv influence koje se primjenjuje intramuskularno ili dubokom supkutanom injekcijom, mogu se pojaviti sljedeće reakcije:
English: Hold the system by placing the thumb and middle finger only on the finger pads; the index finger remains free.
Croatian: Držite sustav palcem i srednjim prstom položenim isključivo na utorima za prste.
English: The vaccine was immunogenic in mice and rabbits.
Croatian: Cjepivo pokazuje imunogenost u miševa i kunića.
English: Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed.
Croatian: Nakon cijepljenja protiv influence, uočeni su lažno pozitivni rezultati seroloških testova primjenom ELISA metode za dokazivanje antitijela protiv HIV-1, hepatitisa C i posebno HTLV-1.
English: - This vaccine should under no circumstances be administered into a vein (intravascularly).
Croatian: Ovo cjepivo se niti pod bilo kojim uvjetima ne smije primijeniti u venu (intravaskularno).
English: This leaflet was last revised in {MM/YYYY}.
Croatian: Ova uputa je zadnji puta revidirana {MM/GGGG} Drugi izvori informacija
English: In some cases, redness at the injection site lasted up to 7 days.
Croatian: U nekim slučajevima, crvenilo na mjestu primjene trajalo je do 7 dana.
English: Once the micro-needle has been inserted, maintain a light pressure on the surface of the skin and inject using the index finger to push on the plunger.
Croatian: Kada je mikroigla u koži, održavajte lagani pritisak na površinu kože i injicirajte cjepivo tako da kažiprstom pritisnete klip.
English: Justification for not including Braille is accepted.
Croatian: Prihvaćeno obrazloženje za nenavođenje Brailleovog pisma.
English: Pharmacotherapeutic group: Influenza vaccines, ATC code: J07BB02 Immunogenicity
Croatian: Farmakoterapijska skupina: cjepivo protiv influence ATK oznaka: J07BB02 Imunogenost
English: Neuralgia, febrile convulsions, neurological disorders, such as encephalomyelitis and Guillain-Barré
Croatian: Neuralgija, febrilne konvulzije, neurološki poremećaji, poput encefalomijelitisa i Guillain-Barréovog
English: Most reactions resolved spontaneously within 1 to 3 days after onset.
Croatian: Većina reakcija spontano nestaje unutar 1 do 3 dana nakon pojave.
English: The most common reactions occurring after vaccine administration were local reactions at injection
Croatian: Najčešće reakcije koje su se javljale nakon cijepljenja bile su lokalne reakcije na mjestu primjene.
English: IDflu is given as an injection into the upper layer of the skin (preferably the muscle of the upper arm).
Croatian: IDflu se daje kao injekcija u gornji sloj kože (preporučuje se mišić nadlaktice).
English: Reactions of not known frequency (frequency cannot be estimated from the available data) - Allergic reactions including skin reactions that may spread throughout the body such as hives, severe allergic reactions (anaphylactic reactions), swollen face, tongue or pharynx, difficulty to swallow, hives and difficulties to breathe (angioedema), failure of the circulatory system
Croatian: Reakcije nepoznate učestalosti (učestalost nije moguće utvrditi iz dostupnih podataka) - Alergijske reakcije uključujući kožne reakcije kao što je osip koji se može proširiti po čitavom tijelu, teške alergijske reakcije (anafilaktička reakcija), oteklina lica, jezika ili ždrijela, poteškoće u gutanju, osip i poteškoće u disanju (angioedem), nemogućnost krvožilnog sustava da održi dovoljan dotok krvi u različite organe (šok) što može dovesti do medicinski hitnog
English: Sanofi Pasteur Parc Industriel d'Incarville 27100 Val-de-Reuil France
Croatian: Sanofi Pasteur Parc Industriel d'Incarville 27100 Val-de-Reuil Francuska
English: Immunisation should be carried out on separate limbs.
Croatian: Imunizacija se treba provesti u različite udove.
English: The needle shielding system is designed to cover the micro-needle after use.
Croatian: Sustav zaštite za iglu namijenjen je pokrivanju mikroigle nakon uporabe.
English: Full effect of the vaccine is generally achieved 2-3 weeks after the
Croatian: Potpuni učinak cjepiva obično se postiže za 2 do 3 tjedna nakon cijepljenja.
English: Systemic safety profile of IDflu is similar to the comparator vaccine, adjuvanted or non-adjuvanted,
Croatian: Sistemski sigurnosni profil IDflu-a sličan je onome kod komparativnog, adjuvantiranog ili neadjuvantiranog cjepivaprimjenjenog intramuskularno.
English: IDflu will help to protect you against the three strains of virus contained in the vaccine, or other strains closely related to them.
Croatian: IDflu će Vam pomoći u zaštiti od tri virusna soja sadržana u ovom cjepivu, ili od drugih usko srodnih sojeva.
English: • Vessel inflammation which may result in very rare cases in temporary kidney problems.
Croatian: • Upala krvnih žila koja se u vrlo rijetkim slučajevima može očitovati privremenim poteškoćama
English: Please read the instructions before use
Croatian: Prije primjene cjepiva molimo pročitajte upute za uporabu
English: Posology Individuals 60 years of age and over: 0.1 ml.
Croatian: Doziranje Osobe u dobi od 60 godina i starije: 0,1 ml.
English: It should be noted that the adverse reactions may be intensified.
Croatian: Treba napomenuti da nuspojave mogu biti pojačane.
English: • The vaccine should be allowed to reach room temperature before use.
Croatian: • Cjepivo treba doseći sobnu temperaturu prije primjene.
English: Apparent local reactions after intradermal administration were more frequent than after intramuscular administration of an adjuvanted or non-adjuvanted comparator vaccine.
Croatian: Vidljive lokalne reakcije nakon intradermalne primjene bile su učestalije nego nakon primjene adjuvantiranog ili nedjuvantiranog komparativnog cjepiva intramuskularno.
English: Nevertheless, single and repeated administrations led to transient local erythema and oedema.
Croatian: Međutim, pojedinačna i ponovljena primjena ovog cjepiva dovela je do pojave prolaznog lokalnog crvenila i edema.
English: • Any component that may be present in very small amounts such as eggs (ovalbumin, chicken proteins), neomycin, formaldehyde and octoxinol 9.
Croatian: Bilo koji sastojak koji može biti prisutan u vrlo maloj količini, kao što su jaja (ovalbumin, pileći proteini), neomicin, formaldehid i oktoksinol 9.
English: This vaccine has no or negligible influence on the ability to drive and use machines.
Croatian: Ovo cjepivo ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada na strojevima
English: - Tell your doctor if you have been treated with medicines that may reduce your immune response such as corticosteroids (for example cortisone), medicines against cancer (chemotherapy), radiotherapy or other medicines affecting the immune system.
Croatian: - Obavijestite svog liječnika ukoliko ste primali lijekove koji mogu smanjiti Vaš imunološki odgovor, kao što su terapija kortikosteroidima (npr. kortizon), terapija za liječenje raka
English: IDflu is a vaccine.This vaccine is recommended to help to protect you against flu.
Croatian: Ovo cjepivo je preporučeno kako bi pomoglo zaštititi Vas od gripe.